IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr

Total Income in Q2 FY25 stood at Rs. 532.18 crore

Solvay and Pantys join forces to advance menstrual health and sustainability

Donation drive in São Paulo aims to support 250 young women’s health and environmental responsibility

Shilpa Medicare Q2 FY25 consolidated PAT up 1,008% at Rs. 18 Cr

NABH integrates FOGSI’S maternal health standards across its certification programs

The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs

EMA grants GMP Certificate of compliance to CuraTeQ biosimilars’ Hyderabad facility

The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections

Cupid Q2 FY25 income up 29.7%; PAT up 96.2%

Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%

Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2

Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds

Shilpa Medicare’s acceptance by USFDA of NDA filed by its CDMO partner Unicycive for Oxylanthanum Carbonate

Tata Chemicals Europe to invest Rs. 655 crore on expansion of pharmaceutical grade sodium bicarbonate capacity

Construction of the plant will commence in 2025 with first production expected to be in 2027

USFDA classifies Biocon Biologics’ Biocon Park in Bengaluru as VAI

The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants